Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials  by Collet, Jean-Philippe et al.
Enoxaparin in Unstable Angina Patients Who Would
Have Been Excluded From Randomized Pivotal Trials
Jean-Philippe Collet, MD, PHD,* Gilles Montalescot, MD, PHD,* Erika Fine, MD,*
Jean-Louis Golmard, MD, PHD,† Miles Dalby, MD,* Re´mi Choussat, MD,* Annick Ankri, MD,‡
Raphae¨lle Dumaine, MD,* Claude Lesty, PHD,* Nicolas Vignolles, BSC,* Daniel Thomas, MD*
Paris, France
OBJECTIVES In the present study, we describe the characteristics and examine the anticoagulation levels
and safety of subcutaneous enoxaparin in unstable angina (UA)/non–ST-segment elevation
myocardial infarction (NSTEMI) patients who would not have been eligible in the Efficacy
Safety Subcutaneous Enoxaparin in Non–Q-wave Coronary Events (ESSENCE) and
Thrombolysis In Myocardial Infarction (TIMI)-11B trials.
BACKGROUND It is not known whether the benefit shown with enoxaparin in the selected population of
pivotal trials can be extended to the real world.
METHODS In our center, all patients with UA/NSTEMI are anticoagulated with subcutaneous
enoxaparin adjusted to creatinine clearance. Among 515 consecutive patients, we identified
174 who would not have been eligible for ESSENCE or TIMI-11B (“EP” group for excluded
patients). We evaluated cardiovascular death or non-fatal myocardial infarction (MI), as well
as major and minor bleeding events, at 30 days in the EP group and in patients without any
of the exclusion criteria (“NEP” group for non-excluded patients).
RESULTS This EP group was older, had a higher female/male ratio, and more frequently had a history
of MI or a diagnosis of non-Q MI on admission than the NEP group. The distribution of
the anti-Xa activity was similar in both groups. The bleeding rates (major and minor) at 30
days were similar in the EP and NEP groups (2.3% vs. 2.9%, respectively, p  NS). On
multivariate analysis, the use of glycoprotein IIb/IIIa inhibitors and the presence of
hypertension were the only independent predictors of bleeding found in the whole
population. Compared with the NEP group, the EP group had a fourfold increased rate of
death or MI at 30 days (15.5% vs. 4.1%, p 0.01). On multivariate analysis, the independent
predictors of death or MI at 30 days were NSTEMI on admission, creatinine clearance, and
heart failure.
CONCLUSIONS Patients who do not fit the enrollment criteria of ESSENCE/TIMI-11B have higher risk
baseline characteristics for both bleeding and ischemic events. In these patients, enoxaparin
with dose adjustment to creatinine clearance provides adequate anti-Xa levels and no excess
of bleeding. (J Am Coll Cardiol 2003;41:8–14) © 2003 by the American College of
Cardiology Foundation
There is now strong evidence for the superiority of the
low-molecular-weight heparin (LMWH) enoxaparin over
unfractionated heparin (UH) in the medical management of
patients with unstable angina (UA) and non–ST-segment
elevation myocardial infarction (NSTEMI) (1–3). How-
ever, the populations of these randomized studies are highly
selected, and it is not known how the conclusions of these
studies can be applied to all patients in routine practice.
A considerable proportion of the “real world” population
with UA/NSTEMI does not meet the inclusion criteria of
the randomized pivotal trials performed with enoxaparin
(1–3), and little information is available on the incidence
and risk profile of these patients. Moreover, the safety of
enoxaparin use in this population is unknown. In our center,
all patients with UA/NSTEMI are treated with enoxaparin,
regardless of the baseline characteristics. However, particu-
lar attention is paid to the dosing regimen and monitoring
of the elderly and those with renal failure (4). We therefore
evaluated the baseline characteristics and risk profile of these
patients who would have been excluded from the Throm-
bolysis In Myocardial Infarction (TIMI)-11B and Efficacy
Safety Subcutaneous Enoxaparin in Non–Q-wave Coronary
Events (ESSENCE) trials (excluded patients, or “EP”
group) and compared them with the rest of the population,
resembling more of the patients enrolled in the two enox-
aparin pivotal trials (non-excluded patients, or “NEP”
group). The main objective was to examine, in both groups,
anticoagulation levels and the safety of enoxaparin treat-
ment used in addition to aspirin.
METHODS
Patient population. A total of 515 consecutive patients
with UA/NSTEMI were treated with subcutaneous enox-
aparin in the Pitie´-SAlpe´trie`re Registry on Ischemic coro-
nary Syndromes (PARIS) registry. Admission NSTEMI
was defined by an initial troponin I level 0.2 g/ml. The
only patients excluded from the study were those with
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contraindications to anticoagulant treatment. All the pa-
tients were recruited before the publication of the Clopi-
dogrel in Unstable angina to prevent Recurrent Events
(CURE) trial, and none of them was treated with combined
aspirin and clopidogrel before catheterization (5). The
global risk profile of the patients was assessed with the
TIMI risk score (6).
All patients received a loading dose of aspirin (500 mg
intravenously) followed by 75 to 250 mg/day of oral aspirin,
beta-blockers, and intravenous nitrates, unless these treat-
ments were contraindicated. Patients with a recurrent isch-
emic episode and an elevated troponin I level received
intravenous glycoprotein (GP) IIb/IIIa inhibitors (n  45).
Enoxaparin was used in all patients. Subcutaneous injec-
tions of 1 mg (100 IU)/kg at 12-h intervals were prescribed,
but elderly patients and patients with renal failure received
reduced doses of enoxaparin, as previously described (4,7).
Briefly, when the creatinine clearance was 30 ml/min,
65% of the recommended dose was given (4). In these
patients, the anti-Xa activity was measured 4 h after the
third subcutaneous injection, and, when needed, the enox-
aparin dosage was adjusted, aiming for an anti-Xa activity
between 0.5 and 1.0 IU/ml.
Catheterization was performed at the treating physician’s
discretion, with immediate percutaneous coronary interven-
tion (PCI), if needed. Enoxaparin was never interrupted
before going to the catheterization laboratory, and patients
were scheduled for catheterization within 8 h of the morn-
ing injection (7). The PCI was performed without UH or
additional enoxaparin. Enoxaparin was not restarted after
PCI. In stent-implanted patients, ticlopidine (250 mg
twice a day) or clopidogrel (loading dose of 300 mg, then
75 mg/day) was given for one month to prevent stent
thrombosis.
Definition of EP. Seven exclusion criteria from the ran-
domized ESSENCE or TIMI-11B trials were applied to
the PARIS registry and were used to define the EP group.
The study design including the flow of patients, and the
definitions of the exclusion criteria are given in Figure 1.
Clinical follow-up. In-hospital follow-up was based on a
physical examination, electrocardiogram (ECG), creatine
kinase (CK) levels, and troponin I levels. Troponin I levels
were determined on admission and every 6 h during the first
24 h, then once daily until hospital discharge (6). In case of
recurrent ischemia, troponin I was measured again every 6 h
during the following 24 h. After PCI, CK and troponin I
were measured at the time of sheath removal (10 h after
the morning injection of enoxaparin) and the next morning
Abbreviations and Acronyms
EP  excluded patients
ESSENCE  Efficacy Safety Subcutaneous Enoxaparin
in Non–Q-wave Coronary Events study
GP  glycoprotein
HF  heart failure
LMWH  low-molecular-weight heparin
MI  myocardial infarction
NEP  non-excluded patients
NSTEMI  non–ST-segment elevation myocardial
infarction
PCI  percutaneous coronary intervention
UA  unstable angina
UH  unfractionated heparin
Figure 1. Flow chart of patients in the PARIS registry, including definitions of exclusion criteria and the number of patients in each category. Creat.
Clear.  creatinine clearance; Hb  hemoglobin; LBB  left bundle branch block; NSTEMI  non–ST-segment elevation myocardial infarction; UA
 unstable angina.
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(i.e., roughly 18 h after PCI). All patients in this study were
followed up at one month by means of written question-
naires and telephone interviews. Deaths were classified as
cardiovascular or non-cardiovascular. Recurrent myocardial
infarction (MI) was defined as recurrent chest pain and/or
ECG changes, with at least one of the following criteria:
1) CK greater than two times the upper limit of normal,
with a 50% rise over the previous value, associated with a
positive troponin I test; and 2) the appearance of a new left
bundle branch block or new Q-waves.
Bleeding definitions were adapted from the TIMI crite-
ria. Major hemorrhage corresponded to: 1) bleeding result-
ing in death; 2) bleeding in an intracranial or intraocular
location; 3) a drop in the serum concentration of hemo-
globin 5 g/dl (or 15% of the hematocrit value); and
4) bleeding requiring urgent surgery. Minor bleeding cor-
responded to: 1) any clinically important bleeding that did
not qualify as major (e.g., epistaxis, ecchymosis, hematoma,
or macroscopic hematuria) but with a drop in the serum
concentration of hemoglobin 3 g/dl (or 10% of the
hematocrit value); 2) bleeding not clinically identified but
associated with a drop in the serum hemoglobin concentra-
tion 4 g/dl (or 12% of the hematocrit level); and
3) bleeding that required a blood transfusion of at least 2 U.
The main safety end point was major and minor bleeding
events at 30 days. Cardiovascular death and non-fatal MI
were also evaluated at 30 days.
Statistical analysis. Categorical variables were expressed as
frequencies and percentages, and continuous variables as the
mean value  SEM (except for age, body mass index, and
creatinine clearance, which were given as the mean  SD.
Simple linear regression was used to test the association
between continuous variables. Potential associations be-
tween clinical and biologic parameters were tested by
univariate procedures, using the Student t test and chi-
square test for continuous and categorical variables, respec-
tively. The alpha level was set at 0.05. Independent predic-
tors of either bleeding (bleeding at 30 days) or ischemic
events (death or non-fatal MI at 30 days) were identified
using stepwise multivariate logistic analysis with the SAS
software version 6.12 (SAS Institute, Cary, North Caroli-
na). Variables included in the model were univariate pre-
dictors with p  0.05.
RESULTS
Baseline characteristics. The characteristics of our study
population were those of all comers presenting with UA/
NSTEMI and who therefore had a higher risk profile than
the populations enrolled in ESSENCE and TIMI-11B.
Heart failure (HF) and chronic renal failure were the most
frequent exclusion criteria, the former being present in 16%
of the whole population (47% of the EP population) (Fig.
1). In addition, 19% of all patients were above 80 years of
age; 23% were diabetics; 24% had a prior history of MI; 12%
had severe renal failure; and 42% had NSTEMI on admis-
sion (Table 1). One-third (n  174) of all patients met at
least one of the seven exclusion criteria from the
ESSENCE/TIMI-11B trials (Fig. 1), and 12.6% had two
or more criteria. Compared with the NEP population, the
EP population had a higher risk profile and a significantly
higher TIMI risk score (2.38  0.06 vs. 2.79  0.08, p 
0.01).
The NEP population was more likely to undergo invasive
diagnostic procedures or revascularizations (Table 2). Gly-
coprotein IIb/IIIa inhibitors were more frequently used in
the NEP population than in the EP population.
Anticoagulation profile. All patients were treated with
combined enoxaparin and aspirin. The EP group was
treated for a longer period than the NEP group (5.6  0.5
vs. 4.4  0.2 days, p  0.01). Patients with severe renal
failure (creatine clearance 30 ml/min) were treated with a
Table 1. Baseline Characteristics and Risk Factors in Excluded
and Non-Excluded Patients
Non-Excluded
(n  341)
Excluded
(n  174)
Demographic data
Age (yrs) 62.5  12.7 74.8  12.2*
80 yrs (%) 8.5 39.1*
Female (%) 25.8 38.5*
Risk factors
Smoker (%) 42.8 29.3*
Hypercholesterolemia (%) 42.6 27.6*
Hypertension (%) 43.3 48.8
Diabetes (%) 22.8 24.7
BMI (kg/m2) 26.0  4.6 25.0  5.3
Cardiac history of
MI (%) 19.9 32.2*
CABG (%) 12.3 6.8
PCI (%) 18.4 16.1
Aspirin medication (%) 31.3 36.7
NSTEMI (%) 33.1 59.2*
ST-segment depression (%) 29.5 32.3
Creatinine clearance (ml/min) 82.2  33.6 46.0  27.6*
*Significant difference between non-excluded patients and excluded patients (p 
0.01). Data are presented as the mean value  SD for age, body mass index (BMI),
and creatinine clearance.
CABG  coronary artery bypass graft surgery; MI  myocardial infarction;
NSTEMI  non–ST-segment elevation myocardial infarction; PCI  percutaneous
coronary intervention.
Table 2. Pharmacologic Interventions and Invasive
Diagnostic or Therapeutic Procedures in Excluded and
Non-Excluded Patients
Non-Excluded
(n  341)
Excluded
(n  174)
ADP RA (%) 19.3 14.3
GP IIb/IIIa RA (%) 11.1 4.6*
Coronary angiography (%) 68.6 50.0*
Revascularization (%) 35.4 25.3*
PCI (%) 26.1 20.7
CABG (%) 9.3 4.6
Urgent revascularization (%) 2.0 2.3
*Significant difference between excluded patients and non-excluded patients (p 
0.01).
ADP  adenosine diphosphate (include ticlopidin and clopidogrel); GP 
glycoprotein; RA  receptor antagonists; other abbreviations as in Table 1.
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lower dosage of enoxaparin than those without severe renal
dysfunction (creatine clearance 30 ml/min) (0.70  0.07
vs. 0.90  0.08 mg/kg, p  0.001). A dose adjustment was
performed in 47% of the EP group that corresponded to
patients with severe renal failure. Among the whole popu-
lation, 94.4% of the patients had an anti-Xa level above
0.5 IU/ml when measured after the third injection or at the
time of catheterization. Most of them were close to the
upper limit (1 IU/ml). Although the EP population was at
a higher risk of accumulation of enoxaparin (i.e., advanced
age, renal dysfunction, longer treatment duration, the dis-
tribution of the anti-Xa activity did not differ from that of
the NEP group (Fig. 2). The average anti-Xa activity was
slightly lower in EP group than in the NEP group (0.87 
0.03 vs. 0.97  0.02 IU/ml, respectively, p  0.01),
reflecting the adequate adjustment of enoxaparin doses in
elderly patients and in patients with renal failure, conditions
that are associated with a risk of overdosage. Indeed,
patients with chronic renal failure (creatine clearance
30 ml/min) had anti-Xa levels similar to those of patients
without severe renal dysfunction (0.85  0.05 vs. 0.95 
0.02, p  NS). Finally, the anti-Xa activity of patients 80
years of age did not differ from that of patients80 years of
age (0.94  0.02 vs. 0.92  0.05, respectively, p  NS).
Bleeding at 30 days. The use of enoxaparin was well
tolerated in both groups of patients, with 2% rates of
major bleeding at 30 days. No significant difference was
observed between the EP and NEP populations regarding
the incidence either of major bleeding events or of all
bleeding events (Fig. 3). On univariate and multivariate
analyses, hypertension and the use of GP IIb/IIIa inhibitors
were the only predictors of bleeding (both major and minor)
(Table 3). Although differences existed, age, female gender,
severe chronic renal failure, invasive strategies, and the use
of adenosine diphosphate receptor antagonists were not
independent predictors of bleeding. Regarding the group
with severe renal failure (creatine clearance 30 ml/min),
the bleeding rate (both major and minor) did not differ
significantly from that of patients with a creatine clearance
30 ml/min (4.7% vs. 2.5%, p  0.53).
Ischemic events at 30 days. One-month follow-up was
available in 88.5% of the patients. There was a fourfold
increase in the end points of both death and death or MI in
the EP group compared with the NEP group (Fig. 4).
Among the pre-specified exclusion criteria used in the
PARIS registry, HF and severe renal dysfunction were
factors strongly associated with adverse clinical outcomes on
univariate analysis (Table 4). In the multivariate model, HF,
creatinine clearance, and NSTEMI on admission were the
only independent predictors of death or MI at 30 days
(Table 4).
On univariate analysis, the TIMI risk score was signifi-
cantly increased in patients with an adverse outcome, in the
whole population (Table 4) and in the NEP group (3.3 
0.3 vs. 2.3  0.1 in patients with and without death or MI
at 30 days, respectively; p 0.001), but not in the EP group
(3.0  0.2 vs. 2.7  0.1 in patients with and without death
or MI at 30 days, respectively; p  0.14). On multivariate
analysis, the TIMI risk score did not predict outcome.
Figure 2. Anti-Xa activity in excluded and non-excluded patients mea-
sured after the third injection or just before the coronary angiogram. The
distribution of anti-Xa activity matches perfectly in both groups. Nearly all
patients (94.4%) had an anti-Xa level above the lower limit of the
therapeutic range (0.5 IU/ml), most of them being close to the upper limit
(1 IU/ml).
Figure 3. Rates of bleeding events at 30 days in excluded and non-excluded
patients. There were no significant differences between the two groups.
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DISCUSSION
This study demonstrates that UA/NSTEMI patients who
would have been excluded from the randomized enoxaparin
trials can be safely treated with a weight-adjusted regimen
of subcutaneous enoxaparin, as long as particular attention is
paid to age and renal function to further adjust the dosing
regimen. The EP population represents a high-risk group of
patients who had a fourfold increase in death or MI at 30
days. Hypertension and the use of GP IIb/IIIa inhibitors
were the only predictors of bleeding found in our study
population.
There is strong evidence that antithrombin therapy is
beneficial in UA/NSTEMI patients and that subcutaneous
enoxaparin is superior to UH in this setting (1–3). How-
ever, this demonstration has been obtained in selected
populations, and it is not known whether these results can
be applied to all comers who present with UA/NSTEMI,
including those who would have been excluded from these
randomized trials. Furthermore, the safety of enoxaparin in
a population at a high risk of bleeding and with a high
percentage of elderly, renal dysfunction, and HF remains to
be determined. In the present study of 515 unselected
consecutive cases, one-third had at least one exclusion
criterion of the ESSENCE/TIMI-11B trials. This propor-
tion is certainly underestimated because only the most
relevant exclusion criteria of the randomized trials were
quoted in our PARIS registry and this may have decreased
the differences between the two populations.
Renal failure was present in one-third of the EP popu-
lation and is certainly one of the most frequent exclusion
criterion found in all comers who have a serious risk of
bleeding. Scant clinical data are available on the safety and
efficacy of LMWH in UA patients with renal insufficiency
(4,8,9). Renal insufficiency has been shown to be a risk
factor for bleeding (10), and the safety of LMWH has been
questioned in patients with low creatinine clearance, be-
cause of the risk of accumulation over time. Our strategy of
reducing the dose and monitoring the anti-Xa activity in
these patients appears to be effective because the anti-Xa
levels in renal failure patients were comparable to those of
patients without renal failure, although the treatment dura-
tion was found to be significantly longer in those with renal
failure. The average enoxaparin dosage was significantly
lower in renal failure patients than in patients with no severe
renal dysfunction, reflecting the dose adjustment. These
results highlight the importance of anti-Xa monitoring to
avoid accumulation of anticoagulant activity and to limit the
risk of bleeding in this specific subset. It further supports
previous findings showing that two-thirds of the recom-
mended dose produces an adequate anticoagulation level in
most patients with severe chronic renal failure (4).
The similar low rate of bleeding events reported in the
NEP and EP groups further confirms the efficacy of our
strategy and the excellent anticoagulation profile of enox-
aparin in the EP group, with reduced dosing and adjust-
ment according to anti-Xa activity if necessary. Indeed, the
rate of bleeding in our study compares favorably with that of
the ESSENCE and TIMI-11B trials (2,3). Age and severe
renal failure are frequently found to be risk factors for
bleeding (10), and one would have expected the EP group to
have a much higher rate of bleeding considered in absolute
terms as well as in comparison with the NEP group. Neither
renal function nor age was a predictor of bleeding in our
Figure 4. Rates of major coronary events at 30 days in excluded and
non-excluded patients. **p  0.001 between the two groups.
Table 3. Predictors of Major or Minor Bleeding in the Whole Population
Incidence of Bleeding
With/Without
Criterion (%)
p Value
(Univariate
Analysis)
p Value
(Multivariate
Analysis)
Odds Ratio
(95% CI)
Age 80 years 4.1/2.4 0.15 —
Female gender 4.5/1.9 0.17 —
BMI 23 kg/m2 3.3/2.3 0.73 —
Hypertension 4.3/1.4 0.05 0.049 3.3 (1.0–10.8)
Creatinine clearance
30 ml/min
4.7/2.4 0.53 —
Killip class 3 2.8/2.4 0.99 —
Cardiac catheterization 2.8/2.6 0.9 —
ADP RA 4.4/2.3 0.4 —
GP IIb/IIIa RA 10.9/1.9 0.002 0.0014 6.6 (2.1–20.8)
ADP RA  GP IIb/IIIa RA 15.0/2.2 0.006 —
BMI  body mass index; CI  confidence interval; other abbreviations as in Table 2.
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study. These findings suggest that the superiority of enox-
aparin over UH in providing more effective and stable
anticoagulation (7,11,12) may also apply to the EP popu-
lation, which showed a good safety profile. In contrast, the
use of GP IIb/IIIa inhibitors was an independent predictor
of bleeding in our study.
The extremely high rate of acute coronary events at 30
days is striking and confirms that the EP population has a
much higher risk than the NEP population. Interestingly,
the most frequent criteria used to define the EP group were
renal failure and HF, both of which predicted major
ischemic events at 30 days. The present study also highlights
that kidney function is a major indicator of vascular risk, as
previously reported in the Minnesota Heart Survey study
(13). However, renal failure is a common exclusion criterion
in randomized trials evaluating antithrombotic drugs. Ob-
viously, clinical trials focusing on patients with renal failure
would be necessary to better assess enoxaparin and other
antithrombotic drugs in this high-risk subgroup (8). This
high rate of coronary events in the EP group may also reflect
less aggressive strategies in these patients, driven mainly by
the risk profile. Indeed, the EP population was less fre-
quently referred to the catheterization laboratory, less fre-
quently underwent coronary revascularization, and had less
aggressive pharmacologic interventions. These patients are
also often excluded from studies evaluating aggressive strat-
egies. Patients 75 years of age were excluded in the
FRagmin during InStability in Coronary artery disease
(FRISC) II trial, and those with severe renal insufficiency or
HF were excluded from the TACTICS-TIMI 18 trial
(14,15) and the TIME study (16). In addition, although age
was not an exclusion criterion, patients 65 years of age
represented 15% of the whole population in the TIMI-
11B and ESSENCE trials (17).
Whether more aggressive antithrombotic and invasive
approaches would be beneficial in the EP group remains to
be established, granted the fact that this group had a higher
risk of bleeding and ischemic events (10,18). There is also
evidence that GP IIb/IIIa inhibitors are effective in patients
with severe renal failure (19), but they had an increased risk
of bleeding in our EP group (10). Whether a dose adjust-
ment of GP IIb/IIIa inhibitors is also necessary in the
elderly and in those with renal failure remains to be
explored. Finally, it remains to be shown whether the
association of enoxaparin and clopidogrel would have a
better risk/benefit ratio in the EP group. Renal failure and
severe congestive HF were also exclusion criteria in the
CURE study (5).
Conclusions. This study first confirms that a significant
proportion of all comers presenting with UA/NSTEMI
would have been excluded from randomized pivotal trials
performed with enoxaparin. It also suggests that these
patients can be treated safely with enoxaparin, with a
specific dose adjustment in patients with low creatinine
clearance. Whether the benefit of enoxaparin in terms of
reducing ischemic events is similar in the EP and NEP
populations cannot be shown from the present data.
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